Actively Recruiting
A Phase 2 Study of HB0017 in Psoriasis Patients
Led by Huabo Biopharm Co., Ltd. · Updated on 2025-09-15
200
Participants Needed
18
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
CONDITIONS
Official Title
A Phase 2 Study of HB0017 in Psoriasis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects aged 18-75 years (inclusive)
- Chronic plaque psoriasis for at least 6 months prior to randomization
- Psoriasis Area Severity Index (PASI) of 12 or higher and body surface area affected by psoriasis of 10% or more
- Static Physician Global Assessment (sPGA) score of 3 or higher
- Suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- Able to use effective contraception from screening to 6 months after last dose
You will not qualify if you...
- Forms of psoriasis other than chronic plaque-type (such as pustular, erythrodermic, or guttate psoriasis) at screening or baseline
- Drug-induced psoriasis
- Ongoing use of prohibited treatments
- Any active infection other than common cold within 14 days
- Serious infection requiring hospitalization or intravenous anti-infective treatment within 1 month prior to randomization
- Previous treatment with any drug directly targeting IL-17 or IL-17 receptor
- Use of other biologic agents within specified washout periods before randomization
- History of inflammatory bowel disease or other serious autoimmune disease
- Previous diagnosis of serious mental illness such as anxiety, depression, or suicidal tendency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Actively Recruiting
2
Southern Medical University Dermatology Hospital
Guangzhou, Guangdong, China
Actively Recruiting
3
Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
4
Wuxi Second People's Hospital
Wuxi, Jiangsu, China
Actively Recruiting
5
Jiangsu University Affiliated Hospital
Zhenjiang, Jiangsu, China
Actively Recruiting
6
Jilin University Second Hospital
Changchun, Jilin, China
Actively Recruiting
7
Shandong First Medical University Affiliated Dermatology Hospital
Jinan, Shandong, China, 0531
Not Yet Recruiting
8
Jining First People's Hospital
Jining, Shandong, China, 0531
Actively Recruiting
9
Xingtai People's Hospital
Xingtai, Shandong, China, 0531
Actively Recruiting
10
Shanxi Medical University Second Hospital
Taiyuan, Shanxi, China
Actively Recruiting
11
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Actively Recruiting
12
Chongqing Traditional Chinese Medicine Hospital
Chongqing, Sichuan, China
Actively Recruiting
13
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
14
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
15
Jiaxing First Hospital
Jiaxing, Zhejiang, China
Actively Recruiting
16
Wenzhou Medical University Affiliated First Hospital
Wenzhou, Zhejiang, China
Actively Recruiting
17
Guangdong Provincial People's Hospital
Guangzhou, China
Actively Recruiting
18
Ningbo Second Hospital
Ningbo, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here